Marker Therapeutics (MRKR) AI Stock Analysis

• Market Cap: $12.21M
• Dividend Yield: N/A
• Average Volume (3M): 184.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: -3.23%
• EPS Growth: 38.05%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -1.20
• Shares Outstanding: 10,709,005
• 10 Day Avg. Volume: 68,763
• 30 Day Avg. Volume: 184,420
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.51
• Price to Cash Flow (P/CF): 2.30
• P/FCF Ratio: 2.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.17
• Price Target Upside: 580.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Marker Therapeutics is in a challenging financial position with promising revenue growth overshadowed by significant net losses and cash flow issues. Technical indicators show bearish trends, although there might be short-term buying opportunities. The lack of immediate valuation appeal and absence of earnings calls or corporate events further weigh down the stock's potential, resulting in a low overall score.

Positive Factors

Clinical Progress

Preliminary data from the Phase 1 APOLLO study showed encouraging safety and efficacy results in lymphoma patients who relapsed after anti-CD19 CAR-T cell therapy.

Financial Funding

MRKR secured more than $13 million in non-dilutive funding to advance its lead product MT-601.

Negative Factors

FDA Approval Risk

There is a significant risk that Marker Therapeutics may not gain FDA approval, which would prevent it from becoming a commercial company.

Financial Risk

Marker Therapeutics' success is highly dependent on producing positive pivotal data for MT-601, obtaining FDA approval, and launching this experimental therapy, making the financial risk for this stock high.

Marker Therapeutics Business Overview & Revenue Model

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

How the Company Makes Money

Marker Therapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future product sales. Additionally, the company may receive funding from grants and research agreements to support the development of its therapeutic candidates. As a clinical-stage company, Marker Therapeutics does not yet generate revenue from product sales, as its products are still undergoing clinical trials and have not yet received regulatory approval for commercialization.

Marker Therapeutics Financial Statement Overview

Summary

Marker Therapeutics faces substantial financial difficulties, with ongoing losses and negative cash flows. Despite revenue growth and a debt-free balance sheet, the company needs to address operational inefficiencies and improve profitability to enhance financial stability and investor confidence.

Income Statement

Marker Therapeutics has faced significant challenges in its income statement, characterized by consistent net income losses, with a TTM net profit margin of -178.55%. The revenue growth rate from 2023 to TTM shows improvement at 62.90%, but the company still struggles with high negative EBIT and EBITDA margins, indicating ongoing operational inefficiencies.

Balance Sheet

The balance sheet reveals a favorable debt-to-equity ratio of 0, indicating no long-term debt and a strong equity position relative to liabilities. However, the equity ratio has decreased over time, standing at 68.30% in TTM, reflecting reduced asset coverage by equity. The return on equity remains negative due to continued net losses, posing a challenge for future profitability.

Cash Flow

Cash flow analysis shows negative operating cash flow and free cash flow, with a TTM free cash flow to net income ratio of 0.89. Although there was a reduction in cash flow deficits compared to previous periods, the consistent negative cash flows highlight liquidity concerns and dependency on external financing.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
5.40M	3.31M	9.00M	1.24M	466.79K	213.19K
	Gross Profit
203.52K	-7.11M	5.32M	-1.92M	-18.41M	-12.55M
	EBIT
-10.19M	-14.58M	-29.95M	-39.48M	-28.89M	-22.53M
	EBITDA
-10.19M	-11.79M	-19.79M	-36.32M	-27.63M	-22.03M
	Net Income Common Stockholders
-9.63M	-14.05M	-29.92M	-41.87M	-28.53M	-20.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
21.37K	15.11M	11.78M	42.35M	21.35M	43.90M
	Total Assets
149.93K	17.13M	34.42M	68.14M	45.61M	46.36M
	Total Debt
485.00K	0.00	7.62M	11.87M	12.26M	484.38K
	Net Debt
463.63K	-15.11M	-4.17M	-30.48M	-9.10M	-43.42M
	Total Liabilities
1.24M	3.07M	14.82M	24.15M	18.27M	2.27M
	Stockholders Equity
-1.09M	14.05M	19.60M	43.99M	27.34M	44.09M
Cash Flow		Free Cash Flow
-8.57M	-16.44M	-31.92M	-30.41M	-29.29M	-18.66M
	Operating Cash Flow
-8.57M	-16.44M	-26.97M	-27.28M	-18.86M	-18.28M
	Investing Cash Flow
-18.66M	18.66M	-4.95M	-3.13M	-10.43M	-374.98K
	Financing Cash Flow
100.54K	1.11M	202.13K	52.56M	6.74M	816.48K

Marker Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Negative. The current price of 1.2 is below the 20-day moving average (MA) of 1.31, below the 50-day MA of 1.58, and below the 200-day MA of 3.19, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 37.92 is Neutral, neither overbought nor oversold. The STOCH value of 32.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRKR.

Marker Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
IOVA	48 Neutral	$1.09B	―	-57.48%	―	13698.99%	31.46%
ADAP	46 Neutral	$50.42M	―	-273.36%	―	194.23%	45.50%
CRSP	46 Neutral	$2.92B	―	-19.20%	―	-89.95%	-123.71%
BLUE	36 Underperform	$47.78M	―	-295.35%	―	184.12%	31.92%
KPTI	36 Underperform	$31.48M	―	41.08%	―	-0.55%	49.85%
MRKR	34 Underperform	$12.21M	―	-65.81%	―	-3.23%	38.05%

Marker Therapeutics Corporate Events

Marker Therapeutics Grants Stock Options to Directors

On February 12, 2024, Marker Therapeutics’ Board of Directors approved a discretionary award of 30,000 stock options to each of three non-employee directors. These stock options vest annually over three years, aligning with the company’s strategic compensation plan to incentivize leadership and potentially enhance company performance.